WALTHAM, Mass., Aug. 1, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it will present at the upcoming Leerink Swann Life Science Tools & Diagnostics Roundtable on Wednesday, August 3, 2011 at 8:20 a.m. Eastern Time. Pieter Muntendam, MD, President and CEO of the Company, will participate in a roundtable discussion entitled "Diagnostics: Existing and Emerging Opportunities." He will then present an overview of BG Medicine at 10:50 a.m. Eastern Time. The corporate presentation will be available to the public through a webcast accessible by visiting: http://wsw.com/webcast/leerink22/bgmd/ or the "Investors" section of the Company's website at www.bg-medicine.com. Replays will be available for 30 days after the presentation.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs. The Company recently launched the BGM Galectin-3TM test for use in patients with heart failure, the first novel blood test for cardiac disease cleared by the U.S. F.D.A. in five years. BG Medicine also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8765